Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published online in The Lancet Infectious Diseases.
The results are significant as public health experts have long warned that the parasite responsible for most malaria cases, Plasmodium falciparum, is developing resistance to widely used treatments. New medications are needed to build up secondary defenses against drug-resistant strains of the parasite.
The drug, called AQ-13, was able to clear the parasite responsible for the disease within a week, matching the effectiveness of the most widely used treatment regimen.
“The potential long-term implications are bigger than one drug. The conceptual step here is that if you understand the resistance well enough, you may be actually be able to develop others as well.”
Dr. Donald Krogstad
“The clinical trial results are extraordinarily encouraging,” said Dr. Donald Krogstad, senior author and professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine. “Compared to the current first-line recommendation for treatment of malaria, the new drug comes out very well.”
Mosquitoes infected by a parasite spread malaria, causing more than 200 million illnesses across the globe and more than 400,000 deaths annually. For decades, chloroquine was used to treat malaria until Plasmodium falciparum developed resistance. Now, a drug combination — artemether and lumefantrine — is the primary treatment for malaria although resistance is also developing to the drug combination in some countries.
Researchers recruited 66 adult men in Mali with uncomplicated malaria, which is defined as malaria that isn’t life threatening. Half were treated with AQ-13 and the other half received artemether and lumefantrine. Both drug groups had similar cure rates. However, five participants in AQ-13 group left the study or were lost to follow-up and two participants in the artemether/lumefantrine group had late treatment failures with recurrence of their original infections.
Researchers hope to expand testing of the drug to more participants, including women and children, before it can be widely recommended as a new treatment. Krogstad said that the same biotechnology that helped the team develop the new drug has also identified similar drugs that also hold promise against drug-resistant parasites.
The Latest on: Malaria
- Breaking the malaria cycle on December 14, 2017 at 3:02 pm
In spite of the huge amount that government, both at the federal and state levels, spends on the provision of curative drugs with the support from the Global Fund, malaria has remained endemic in Nigeria. Indeed, it is impossible to calculate the actual ... […]
- A new research agenda to accelerate malaria elimination and eradication on December 14, 2017 at 1:47 pm
A world free of malaria would present enormous benefits in terms of health, equity and economy. The WHO has set ambitious goals for reducing the burden of malaria, and 21 countries have been identified as having the potential to eliminate local ... […]
- Researchers identify way to weaken malaria parasites against popular drug treatment on December 14, 2017 at 11:47 am
Indiana University School of Medicine researchers have identified a way to block the ability of parasites that cause malaria to shield themselves against drug treatments in infected mice--a finding that could lead to the development of new approaches to ... […]
- S. African health authorities issue malaria alert on December 14, 2017 at 10:22 am
CAPE TOWN, Dec. 14 (Xinhua) -- There is an increased risk of developing malaria in parts of South Africa following a very busy 2017 malaria season in the entire Southern African region, health authorities warned on Thursday. An increased number of severe ... […]
- People stay vigilant to the threat of malaria, even when infections fall on December 14, 2017 at 9:39 am
Gabriel Picone receives funding from the Fogarty International Center for this project. Bénédicte Apouey received funding from the Fogarty International Center -- a branch of the United States government's National Institutes of Health -- for this project. […]
- BRIEF-Glaxosmithkline Submits Regulatory Application For Single-Dose Tafenoquine For Treatment Of Plasmodium Vivax Malaria on December 14, 2017 at 2:23 am
* GSK PLANS TO PROGRESS REGULATORY FILINGS IN OTHER COUNTRIES IN 2018 Further company coverage: ([email protected]) Our Standards:The Thomson Reuters Trust Principles. […]
- Question 2: Are three malaria tests necessary in children returning from the tropics with fever? on December 13, 2017 at 6:24 am
A chatty, 4 year-old girl is brought to the emergency department (ED) by her mother with a 3-day history of fever and loose stool. They returned from Nigeria 7 days earlier, having visited friends and relatives for the school holidays. Clinical ... […]
- Market Overview of Malaria Vaccine pipeline Landscape 2024 on December 13, 2017 at 4:18 am
As per WHO, nearly 50% of the global population is at the risk of malaria, there were 214 million malaria cases reported in 2015. In 2012, more than 24 active malaria vaccine candidates were in clinical development and more than 12 were in preclinical ... […]
- In Sao Tome, funding fears overshadow gains against malaria on December 11, 2017 at 7:58 pm
Sao Tome (Sao Tome and Principe) (AFP) - A big roadside poster announces a "Pest Control Campaign" in Sao Tome and Principe, with a man in a white face mask wielding an insecticide spray fuelled by a tank on his back. The island nation in the Gulf of ... […]
- Global malaria drugs market predicted to grow at a CAGR of +19% on December 10, 2017 at 5:47 am
This report provides a comprehensive analysis of the present Global Drugs for Malaria Market . It starts with the basic overview of the industry and then goes into each and every detail. - Agency -. A comprehensive analysis of the Global Drugs for Malaria ... […]
via Google News and Bing News